Court Restores Ban on Controversial Diabetes Drugs

The Delhi High Court recently reinstated a ban on two fixed-dose combination (FDC) diabetes drugs, reigniting discussions surrounding these medications and pioglitazone specifically. This FDC ban was previously overturned by a single judge but has now been upheld by the High Court, reinforcing regulatory powers for public health interventions.

The ruling comes after a series of expert reviews and legal battles concerning FDCs, which combine multiple drugs into a single dosage. While beneficial for certain conditions like HIV and TB, concerns have been raised about FDCs driven by commercial interests rather than scientific evidence, with some formulations containing up to seven drugs.

Medical professionals express concern over pioglitazone's inclusion, citing its potential to cause or worsen heart failure, decrease bone density, increase fracture risk, and its association with bladder cancer. Although not outright banned, pioglitazone carries warnings in the US and is used cautiously. Experts argue that FDCs prevent individualized dosing and that these specific combinations are not essential.

This judicial decision is seen as a victory for rational product regulation in India. Public health advocates are also calling for greater transparency in drug approval evidence and prescribing information for both consumers and professionals.